MARLBOROUGH, Mass. — New data on Hologic’s (Nasdaq: HOLX) breast cancer detection technologies will be presented at the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, Illinois.
“At Hologic, we’re committed to advancing our technologies to support women at every stage of the breast health continuum, and real-world studies are a critical part of that,” said Mark Horvath, President of Breast & Skeletal Health Solutions at Hologic. “Artificial intelligence is increasingly becoming a critical tool in mammography, and we are encouraged to see data from multiple studies underscoring its potential to help radiologists work more efficiently without sacrificing quality.”
In a study led by Dr. Manisha Bahl, M.D., MPH, FSBI, Associate Medical Director of Quality at Mass General Brigham and Associate Professor of Radiology at Harvard Medical School, researchers at Massachusetts General Hospital evaluated Hologic’s 3DQuorum imaging technology. The retrospective analysis reviewed more than 160,000 screening mammography exams and compared cancer detection rates before and after adoption of 3DQuorum, which uses artificial intelligence to reduce the number of three-dimensional imaging slices radiologists need to review without compromising image quality, sensitivity or accuracy.
According to the findings, there was no significant difference in cancer detection rates following implementation. With ongoing radiologist shortages across the U.S., these results suggest the technology could streamline workflows and save valuable clinical time while maintaining high effectiveness in cancer detection.
“AI holds boundless potential in healthcare that we are only beginning to tap into, with a wide range of applications that can improve patient care,” said Dr. Manisha Bahl, M.D., MPH, FSBI. “In breast cancer screening, technologies like 3DQuorum help radiologists work more efficiently while still delivering the same high-quality care to every woman. By streamlining the review process, AI allows us to focus our attention where it matters most: finding cancers early and supporting each patient with confidence.”
A separate study, led by Professor Yan Chen, Ph.D., Chair of Digital Screening and Head of the Digital Cancer Screening Research Group at the University of Nottingham in the U.K., reviewed Hologic’s Genius AI Detection solution alongside 108 radiologists in the U.S. and U.K. In the analysis, radiologists examined 75 challenging breast cancer cases while the AI system assessed the same scans.
The technology performed similarly to radiologists overall. It detected more cancers, though it demonstrated lower specificity, meaning it flagged more cases that did not turn out to be cancer. Although still underway, the study’s initial findings suggest the potential value of AI in environments that rely on double reading and face staffing constraints.
In addition to the research being presented at RSNA, Hologic will feature several innovations, including the Genius AI Detection suite of products, leading breast surgery technologies, and the next-generation Envision Mammography Platform with tilt positioning designed to adapt to patients. The company also plans to host medical education events throughout the meeting, covering advancements in artificial intelligence, contrast-enhanced mammography and breast surgery.
